Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

THR 317

Next Previous
Drug Profile

THR 317

Alternative Names: Anti-placental growth factor monoclonal antibody; Anti-PlGF; Anti-PlGF monoclonal antibody; R-7334; RG 7334; RO-5323441; TB 403; THR-317; αPlGF

Latest Information Update: 09 May 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioInvent International; ThromboGenics
  • Developer BioInvent International; Oncurious; Oxurion
  • Class Anti-inflammatories; Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Placenta growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Medulloblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Age-related macular degeneration; Diabetic macular oedema; Diabetic retinopathy; Glioblastoma; Liver cancer; Medulloblastoma; Retinal telangiectasis; Solid tumours

Most Recent Events

  • 12 Apr 2021 Safety, efficacy and pharmacodynamics data from a phase I/IIa trial in Medulloblastoma released by Oncurious NV
  • 27 Dec 2019 THR 317 is available for licensing as of 27 Dec 2019. https://www.oxurion.com/ (Oxurion Website, December 2019)
  • 19 Dec 2019 Discontinued - Phase-I/II for Medulloblastoma (In adolescents, In children, Second-line therapy or greater) in USA (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top